30.26
+8.15%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adaptive Biotechnologies
From its filings with the US Securities and Exchange Commission
Adaptive Biotechnologies is based in Seattle, Washington and is incorporated in Washington. Its shares trade on Nasdaq under the ticker ADPT. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $277.0m and a net loss of $59.5m. At that date it held total assets of $512.7m and shareholders' equity of $218.8m.
Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.
In 2024, we reorganized our company around two main businesses: the “MRD business,” consisting of clinical assessment of minimal residual disease (“MRD”) in lymphoid malignancies, and “Immune Medicine” or the “IM business,” with a focus on creating applications and products based on unique capabilities to connect the adaptive immune response to disease.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 27 Jun 2019
- Employees
- 624
- Website
- adaptivebiotech.com ↗
- Head office
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Incorporated in
- WA
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Chad RobinsChairman of the Board, Chief Executive Officer, Co-Founder, since 2009$5.0m
- Ms. Julie RubinsteinPresident, Chief Operating Officer$2.6m
- Dr. Harlan RobinsCo-Founder, Chief Scientific Officer$4.5m
- Mr. Kyle PiskelChief Financial Officer$1.3m
- Mr. Francis LoChief People Officer
- Dr. Sharon BenzenoChief Commercial Officer - Immune Medicine$1.8m
- Ms. Susan BobulskyChief Commercial Officer - MRD
- Mr. Peter NeupertLead Independent Director$355,000
- Ms. Michelle GriffinIndependent Director$330,000
- Dr. Robert HershbergIndependent Director$325,000
- Dr. Katey OwenIndependent Director$310,000
- Ms. Karina CalzadillaVice President - Investor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 37
- Environment
- 35
- Social
- 68
- Governance
- 8
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.